MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other analysts have also recently commented on MXCT. Stephens initiated coverage on shares of MaxCyte in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 target price for the company. William Blair cut shares of MaxCyte from an “outperform” rating to a “market perform” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, MaxCyte presently has an average rating of “Hold” and a consensus target price of $7.00.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $1.38 on Friday. The stock has a market cap of $147.12 million, a P/E ratio of -3.21 and a beta of 1.23. The firm has a fifty day moving average price of $2.16 and a 200 day moving average price of $2.82. MaxCyte has a 1-year low of $1.36 and a 1-year high of $5.20.

MaxCyte (NASDAQ:MXCT) last released its earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. The firm had revenue of $8.51 million during the quarter, compared to analyst estimates of $9.57 million. Sell-side analysts expect that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Trading of MaxCyte

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its stake in shares of MaxCyte by 123.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock valued at $31,000 after purchasing an additional 4,173 shares during the period. Farther Finance Advisors LLC lifted its stake in shares of MaxCyte by 7,935.4% in the second quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock valued at $26,000 after purchasing an additional 11,665 shares during the period. CWM LLC lifted its stake in shares of MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after purchasing an additional 5,836 shares during the period. May Hill Capital LLC acquired a new stake in shares of MaxCyte in the second quarter valued at about $27,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of MaxCyte in the fourth quarter valued at about $56,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.